(Total Views: 323)
Posted On: 03/16/2022 1:06:51 PM
Post# of 1418
Additionally, the assets include new intellectual property that covers follow-on products based on Tollovir, including new chemical entity (NCE) therapeutic candidates.
Dr. Dorit Arad, PhD, will serve as Chief Technology Officer of 3CL Pharma. Dr. Arad brings extensive experience and access to discoveries related to the development and commercialization of new chemical entities targeting the 3CL protease.
Not just
Tollovid x 2
Tollovir
TolloTest
But wait there's more....
New IP ?
NEC therapeutic candidates??
Pretty pretty pretty pretty interesting.
And Dr. Arad is joining both companies, sound like she's impressed.
"We are in full alignment with the Todos team for the development and commercialization of Tollovir and TolloTest...."
"We expect a big opportunity for 3CL Pharma ahead."
Dr. Dorit Arad, PhD, will serve as Chief Technology Officer of 3CL Pharma. Dr. Arad brings extensive experience and access to discoveries related to the development and commercialization of new chemical entities targeting the 3CL protease.
Not just
Tollovid x 2
Tollovir
TolloTest
But wait there's more....
New IP ?
NEC therapeutic candidates??
Pretty pretty pretty pretty interesting.
And Dr. Arad is joining both companies, sound like she's impressed.
"We are in full alignment with the Todos team for the development and commercialization of Tollovir and TolloTest...."
"We expect a big opportunity for 3CL Pharma ahead."
(1)
(0)
